Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of JTT-662 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 Clinical Trial

Official title:

Single-blind, Randomized, Placebo-controlled, Multiple Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JTT-662 Administered for 28 Days in Subjects With Type 2 Diabetes Mellitus on Metformin Monotherapy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04465877
• Other study ID #: AT662-U-20-003
• Status: Completed
• Phase: Phase 1
• Start date: June 15, 2020
• Est. completion date: February 17, 2021

Study information

• Verified date: April 2022
• Source: Akros Pharma Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of JTT-662 administered once daily for 28 days in subjects with Type 2 diabetes mellitus (T2DM) who are receiving metformin monotherapy

Recruitment information / eligibility

• Status: Completed
• Enrollment: 37
• Est. completion date: February 17, 2021
• Est. primary completion date: February 17, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Diagnosis of T2DM for at least 12 weeks prior to the Screening Visit

• Currently treated with a stable oral dose of metformin monotherapy for at least 12 weeks prior to the Screening Visit and until Day -3

• Have a glycosylated hemoglobin (HbA1c) value of between 6.5% and 10.0% at the Screening Visit

• Have a fasting plasma glucose (FPG) value of no more than 280 mg/dL at the Screening Visit and on Day -3

• Body Mass Index (BMI) of 25 to 40 kg/m2 (inclusive)

Exclusion Criteria:

• Known medical history or presence of Type 1 diabetes mellitus, Maturity Onset Diabetes of the Young or secondary forms of diabetes

• Known medical history or presence of diabetic complications

• Have taken anti-diabetic medications (other than metformin) or medications that act mainly in the gastrointestinal tract (e.g., orlistat, acarbose) within 12 weeks prior to the Screening Visit or from the Screening Visit to Day -3

• Have uncontrolled hypertension (systolic blood pressure of at least 160 mmHg or diastolic blood pressure of at least 95 mmHg) at the Screening Visit

• Have impaired renal function (estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2)

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 2

Intervention

Drug:
• JTT-662
Active drug tablets containing JTT-662
• Placebo
Placebo tablets matching in appearance to the active drug tablets

Locations

Country	Name	City	State
United States	Qps-Mra, Llc	Miami	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Akros Pharma Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Subjects With Treatment-emergent Adverse Events	Treatment-emergent adverse event is defined as any adverse event (untoward medical experience occurring to a subject whether or not it is related to the study drug) with an onset date/time at/after the placebo dosing on Day -1.	6 Weeks (from Day -1 to the follow-up visit on Day 42)
Primary	Number of Stools and Type of Stools Based on Bristol Stool Chart	Number of occurrences for each stool type was reported based on their type assessed from Bristol Stool Chart. The Bristol Stool Chart was used to assess the stool shape using a 7-point scale. Where, Type 1 = separate hard lumps, like nuts (hard to pass), Type 2 = sausage-shaped but lumpy, Type 3 = like a sausage but with cracks on the surface, Type 4 = like a sausage or snake, smooth and soft, Type 5 = soft blobs with clear-cut edges (passed easily), Type 6 = fluffy pieces with ragged edges, a mushy stool, Type 7 = watery, no solid pieces; entirely liquid. A score of 1 or 2 indicates constipation while a score of 6 or 7 indicates diarrhea.	7 Weeks (from Day -6 to the follow-up visit on Day 42)
Primary	Trough Concentrations of JTT-662 in Plasma on Days 1, 7, 10, 14, 15, 21 and 28	Trough plasma concentration is the measured concentration at the end of a dosing interval at steady state (taken directly before next administration). Blood samples were collected at specific timepoints to measure trough plasma concentrations of JTT-662 in the subjects randomized to JTT-662 treatment groups.	28 Days
Primary	Change From Baseline in AUEC0-4 for Plasma Postprandial Glucose (PPG) Compared to Placebo on Days 1, 14 and 28	Change from baseline in the AUEC0-4 (area under the observed effect-time curve from the start of breakfast until the 4 hour time point) for PPG were calculated using the corresponding Day -1 value as baseline and compared to the placebo values. Negative values represent greater reduction in PPG from baseline values compared to placebo.	Days 1, 14 and 28